Fueled by remarkable breakthroughs in vaccines and new therapies, a greater understanding and treatment of overall health, and new ways of deploying data to improve patient care, there are now a host of new, dynamic solutions to some of the world’s biggest health challenges. But there is also a sense of unevenness and inconsistency when it comes to opportunities and developments in the space.
CNBC’s Healthy Returns convenes the sharpest minds, bold pioneers and visionary leaders in the health care industry on what they see ahead for treatments and innovations, what’s working, what needs to improve, and what’s on the horizon that will shape health care for the future.
WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
Rosalind (Roz) Brewer joined Walgreens Boots Alliance as Chief Executive Officer in March 2021. She also is a Director on WBA’s Board. Ms. Brewer most recently served as Chief Operating Officer and Group President at Starbucks from October 2017 to January 2021. Prior to Starbucks, she served as President and Chief Executive Officer of Sam’s Club, a membership-only retail warehouse club and division of Walmart, Inc., from February 2012 to February 2017. Ms. Brewer previously held several executive leadership positions with Walmart beginning in 2006.
Prior to joining Walmart, she served as President of Global Nonwovens Division for Kimberly-Clark Corporation, a global health and hygiene products company, from 2004 to 2006, and held various management positions at Kimberly-Clark beginning in 1984.
She currently serves as the Chairperson of the Board of Trustees for Spelman College, where she did her undergraduate work. Ms. Brewer also is a Board Member of VillageMD, World Business Chicago, Business Roundtable and the Smithsonian’s National Museum of African-American History and Culture. Ms. Brewer formerly served on the Board of Directors for Starbucks, Amazon, Lockheed Martin Corporation and Molson Coors Brewing Company. She is currently ranked #6 on Fortune’s 50 Most Powerful Women in Business and was named one of the 25 most influential women by the Financial Times in 2021.
Joaquin Duato is the Chief Executive Officer of Johnson & Johnson and serves on its Board of Directors. As CEO of the world’s largest healthcare company, Joaquin leads a global workforce of 135,000 employees in developing and delivering transformational and innovative healthcare solutions in Pharmaceuticals, MedTech, and Consumer Health.
From his early days in Spain, Joaquin found inspiration by focusing on how healthcare improved patients’ lives. Over the course of three decades with the company, he developed a deep understanding of what’s possible at Johnson & Johnson by working in all business sectors and across multiple geographies and functions. Before being named CEO, Joaquin served as the Vice Chairman of the Executive Committee, where he provided strategic direction for the Pharmaceutical and Consumer Health sectors and oversaw both Information Technology and the Global Supply Chain.
Joaquin’s many accomplishments include driving the transformation of the company’s pharmaceutical business into a global powerhouse by refocusing strategy and investment around core therapeutic areas and areas of greatest unmet need during his tenure as the sector’s Worldwide Chairman. More recently, he oversaw the company’s rapid response to the COVID-19 pandemic and drove coordination of global initiatives to safeguard the health of employees and ensure business and supply chain continuity, so the company’s life-saving medicines and products reached patients and communities in need.
A believer in the power of technology to accelerate progress in healthcare, Joaquin is leading Johnson & Johnson to harness data science and intelligent automation for insight generation so that teams work as a united front, with expertise and purpose, to solve the world’s toughest health challenges.
A dual citizen of Spain and the United States, Joaquin’s international perspective gives him a deep appreciation of diversity in all its forms. He is committed to building an inclusive workforce that reflects the patients J&J serves, evidenced by nearly a decade acting as Executive Sponsor for the African Ancestry Leadership Council ERG.
Joaquin earned an MBA from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona. He lives in Pennsylvania with his wife and two college-aged children.
Dr. Brown graduated from Yale College, where she majored in molecular biophysics and biochemistry. She earned her medical degree from Harvard University. She completed internship and residency programs in medicine at Vanderbilt University, where she also did a fellowship in clinical pharmacology. Dr. Brown joined the faculty of Vanderbilt in 1992 and held a number of leadership positions, serving as chief of the Division of Clinical Pharmacology, associate dean for clinical and translational scientist development, and Robert H. Williams professor before becoming the Hugh J. Morgan Chair of Medicine and physician-in-chief of Vanderbilt University Hospital in 2010.
In 2020, she became Jean and David W. Wallace Dean of Medicine and C.N.H. Long Professor of Internal Medicine at Yale School of Medicine. Dr. Brown has long been committed to medical education and mentorship. At Vanderbilt, she established the Elliot Newman Society to support the development of physician-scientists and co-founded the Vanderbilt Master of Science in Clinical Investigation program. Her research has defined the molecular mechanisms through which commonly prescribed blood pressure and diabetes drugs affect the risk of cardiovascular and kidney disease. In her clinical practice, she has treated patients with resistant and secondary forms of hypertension. Dr. Brown has served as a member of the NIH National Advisory Research Resources Council and the National Heart, Lung, and Blood Advisory Council. She was president of the Association of Professors of Medicine. In 2019, she was elected a Master of the American College of Physicians.Her numerous awards include election to the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. She is a member of the American Association of Arts and Sciences.
World-renowned cardiologist Dr. Henry Ting joined Delta Air Lines in 2021 as the global brand’s Chief Health Officer – a first for a U.S. airline. In his most recent role as Mayo Clinic’s enterprise Chief Value Officer, Dr. Ting became familiar with Delta both as a long-time Medallion customer and, more recently, as a primary COVID-19 advisor who has helped shape Delta’s response since the early days of the pandemic.
From employee testing and cleanliness strategies to operational tactics that reduce the transmission of the virus, Dr. Ting has been a key voice in the health and wellness decisions that have helped Delta strengthen the people-first approach we were known for even prior to the pandemic. As part of the Delta team, Dr. Ting is building on this work to help Delta navigate the pandemic and emerge stronger and better prepared for the future.
Working collaboratively with groups across the airline, Dr. Ting leads Delta in reimagining our approach to health and well-being, utilizing new technologies, artificial intelligence, advanced analytics and innovative partnerships.
In addition to his role at Delta, Dr. Ting retains his title as Professor Emeritus at Mayo Clinic.
Before joining Delta, Dr. Ting served in multiple leadership roles at Mayo Clinic including enterprise Chief Value Officer, clinical practice Chair of the Department of Cardiology and Associate Dean. He also served as S.V.P. and Chief Quality Officer at New York Presbyterian Hospital.
Dr. Ting’s academic focus includes health services research, outcomes research and implementation science. He has lectured worldwide and authored over 200 journal articles, book chapters and publications. In addition, he has served on committees and boards for the U.S. Department of Health and Human Services, U.S. Agency for Healthcare Research and Quality, National Quality Forum and U.S. News & World Report advisory council.
Dr. Ting received his bachelor’s degree in chemistry from Cornell University, Doctorate of Medicine from Harvard Medical School and master’s degree in business administration from the University of St. Thomas.
Dr. Christiana (Chris) Bardon is Co-Managing Partner of BioImpact Capital, an affiliate manager of MPM and leads MPM’s public market investing as portfolio manager for BioImpact Equities (f/k/a Burrage Capital) and the Oncology Impact Funds.
Previously, Chris was a health care analyst at Fidelity Investments covering biotechnology, life-science tools and diagnostics, and she started her career as an analyst at MPM. She currently serves on the Harvard Medical School Board of Fellows and is a Trustee of the American Association for Cancer Research Foundation.
Chris earned her M.D. magna cum laude from Harvard Medical School and her M.B.A. from Harvard Business School. While at Harvard Medical School, she was the recipient of a Howard Hughes fellowship, and she completed her residency in Internal Medicine at the Brigham and Women’s Hospital at Harvard Medical School. She received her M.S./B.S. from the Massachusetts Institute of Technology.
Laura Birk is the Vice President of Human Resources for Barilla America, Inc. where she has been for over 15 years. Laura is responsible for all the talent management and people processes supporting the Americas business which includes Canada, U.S., Mexico and Brazil. She is a Board Member for the company and has the pleasure to serve almost 1,000 employees across the Americas.
Laura’s recently been recognized by OnCon as a 2020 Top 50 Human Resources Professional and Chicago Business Crain’s 2021 Notable Leaders in HR. She also leads a great team who has won several industry awards for diversity, wellness, employee benefits, and talent management and development activities including:
• Catalyst-Workplaces that Work for Woman Winner
• 100% Corporate Equality Index, Best Places to Work for LGBT Equality
• Corporate Equality Award
• Hispanic Alliance for Career Enhancement (H.A.C.E.) Corporate Champion
• Disability Matters: Steps to Success Award
• Corporate University Best in Class (C.U.B.I.C.) Award Winner: Best Job Aligning Learning and Development with Corporate Goals
• Talent Management Best In Class (TAMBIC) Award Recipient
• American Society of Training and Development (ASTD) B.E.S.T. Award Recipient
• Organizational Development Network (ODN)-Chicago Award Recipient
• Dave Thomas Foundation and The Cradle for Best in Class Adoption benefits
Laura serves on the Board for Missouri State University Advisory Board, and former Board Member for the Tyler Clementi Foundation. She supports and volunteers at the Cradle Adoption agency, Special Olympic, Walter & Connie Payton Foundation, Hispanic Alliance Career Enhancement (H.A.C.E.), and several other Diversity and Inclusion organizations.
She received her degree from Drury University and prior to her current role, Laura spent 10 years at Morgan Stanley.
Kathleen Carroll was named Senior Vice President and Chief Human Resources Officer in 2018. She is responsible for global human resources strategies and operations, communications and corporate responsibility that enable the company’s business goals, support a high-performance culture and strengthen the company’s brand as an employer of choice. Kathleen has more than 25 years of experience in leading human resources and organizational strategies to drive business results. Her expertise encompasses leadership development, diversity, equity and inclusion, talent acquisition, employment branding, succession planning, compensation and benefits, and talent analytics.
Prior to Grainger, Kathleen was with First Midwest Bank, where she served as Executive Vice President and CHRO. Prior to that, she held a number of leadership positions with Aon Corporation, which included Global Head of Talent Acquisition and HR Lead for Mergers and Acquisitions. Prior to her roles in HR, she worked in Corporate Development and Strategy where she led strategic initiatives and acquisitions and divestitures. She served as the overall project leader for the creation and development of Aon Hewitt’s Corporate Health Care Exchange business and played a central role in the Aon/Hewitt merger integration.
Kathleen earned a bachelor’s degree in accounting from the University of Missouri and received a master’s degree in business administration from Northwestern University’s Kellogg School of Management.
She currently serves on the boards of directors for the International Women’s Forum and Leadership Greater Chicago, where she serves on the Executive Committee.
W.W. Grainger, Inc., with 2021 sales of $13.0 billion, is a leading broad line distributor with operations primarily in North America, Japan and the United Kingdom. Grainger achieves its purpose, We Keep the World Working®, by serving more than 4.5 million customers worldwide with a wide range of product categories that keep customer operations running and their people safe. The Company also delivers services and solutions, such as technical support and inventory management, to provide tangible value and save customers time and money. Grainger offers more than 2 million maintenance, repair and operating (MRO) products in its High-Touch Solutions assortment and more than 30 million products through its expanding Endless Assortment offering. For more information about the company, please visit www.grainger.com/pressroom.
Gary Désir M.D. is the Beeson Professor of Medicine at the Yale University School of Medicine (YSM) and serves as chair of the Department of Internal Medicine at YSM, and chair of the board of Yale Medicine.
He is a physician-scientist whose work has been funded by the National Science Foundation, National Institute of Health, Department of Veterans Affairs, American Heart Association, and the Robert Wood Johnson foundation. His major contributions to science include the discovery a specific voltage-gated potassium channel that regulates body weight and insulin sensitivity, and the identification of a new growth factor, which he named renalase. He elucidated the pathway through which renalase affects cellular signaling and discovered that the protein can function abnormally and facilitate the development of certain cancers. Hi laboratory is currently focused on developing drugs that can treat cancer by blocking the action of renalase in cancer cells. Dr. Désir is a named inventor on several patents related to the discovery and therapeutic use of renalase, and the development of drugs that modulate renalase signaling in cancer. He is the scientific founder of 2 biotechnology companies focused on developing renalase-based therapies.
Dr. Désir, the first person of African descent to be appointed as chair of a department at YSM, has a strong interest in issues of diversity and social justice. He is the co-founder of the minority organization for retention and expansion (MORE), a faculty group at YSM focused on increasing faculty diversity through mentoring programs and developing resilient social networks. In collaboration with Gordon Geballe, Associate Dean for Alumni and External Affairs at school of Forestry and Environmental Studies, he has worked with L’Hospital Albert Schweitzer in the Artibonite valley in Haiti on integrated projects designed to improve the standard of living in the valley.
He was born in Port-Au-Prince, Haiti. After high school, he immigrated to the US to attend New York University, from which he graduated magna cum laude, with a bachelor’s degree in biology. He was elected to the Phi Beta Kappa Society, and also received New York University’s Founders Day award. Following graduation from Yale University School of Medicine (Cum Laude, Alpha Omega Alpha honor society), he trained in internal medicine and nephrology at Yale New Haven Hospital.
Dr. Désir is married to Dr. Deborah Dyett Désir who practices rheumatology at Yale. They have four children, Carl, Matthew, Christopher and Alexandra, a granddaughter Elodie and a grandson Amari.
Jim D. Dunn, PhD, DHA, DAST, FACHE, is executive vice president and chief people and culture officer for Atrium Health, one of the largest non-profit and leading academic health systems in the United States. As a member of the executive leadership team, Dunn leads teams that focus on the engagement of Atrium Health teammates – from recruitment through retirement – including workforce relations, diversity and inclusion, language services, compensation, benefits, learning and organizational development, teammate health, LiveWELL, recognition, events and HR communications, social impact and health equity.
With more than 30 years of experience, Dunn joined Atrium Health in 2018. Previously, he served as a research scientist with the Georgia Tech Research Institute and the leader of global HR operations for former President Jimmy Carter at the Carter Presidential Center in Atlanta. Additional leadership positions held throughout his career include serving as adjunct and distinguished faculty for multiple universities including the Harvard School of Public Health, MIT Sloan School of Management, Morehouse School of Medicine, Emory University, University of Chicago and the University of Texas at Dallas.
Dunn is a state registered professional mediator, specializing in workplace conflict resolution strategies and a fellow (FACHE) and faculty member of the American College of Healthcare Executives. He was also elected by the US Congress to serve on the Congressional Award Foundation’s National Board of Directors.
Among his many achievements, Dunn has received the Outstanding Business Leader Award from the Dallas Business Journal, the South Dallas Outstanding Leader Award, and the Global Strategic HR and OD Award from the Organizational Development Institute for his work on informal cultures. He also was named among the 2018 and 2020 Most Influential African Americans in Corporate America by Savoy Magazine. Dunn was also selected as a finalist for 2021 CHRO of the Year by HRO Today Association.
Dunn holds Bachelor of Science degrees in chemistry and macro-environmental science from Howard University, a master’s degree in business administration from the Massachusetts Institute of Technology (MIT) and a master’s degree in public health from Emory University. Additionally, he holds doctoral degrees in education, organizational development and healthcare administration from Emory University, Benedictine University and the Medical University of South Carolina, respectively.
Dr. Yvonne Greenstreet joined Alnylam in 2016 as Chief Operating Officer, was promoted to President and COO in 2020, and was appointed as a Director and Chief Executive Officer in late 2021. Yvonne has more than 25 years of experience in the Biopharmaceutical industry, driving strategy and innovation, bringing transformative medicines to patients, and building successful businesses in the US, Europe and globally.
Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer serving on the executive team leading a rapidly growing $16bn division. Prior to Pfizer, she was at GlaxoSmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development. Yvonne had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicines Development and Chief Medical Officer for Europe.
Yvonne trained as a physician and earned her medical degree (MBChB) from The University of Leeds in the UK. She also holds an MBA from INSEAD Business school in France. Dr. Greenstreet serves on the board of directors of Pacira BioSciences, Inc., argenx SE and The American Funds. Additionally, she is in the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and is a member of the Discovery Council of Harvard Medical School.
Mohamad Makhzoumi is Managing General Partner, Healthcare and Head of NEA’s Global Healthcare Investing practice, which typically accounts for 40% of NEA's funds across healthcare services, healthcare IT, biopharma and medical devices. Mohamad’s personal investment practice is primarily focused on the digital health sector where he is currently a Director of Aetion, AllyAlign, Belong Health, Bright Health, Collective Health, Comprehensive Pharmacy Services, Everside Health, Nuvolo, Radiology Partners, Strive Health, Vori Health, and Waymark. Mohamad’s past investments include Bravo Health, CHG Healthcare, DaVita NephroLife, DSI Renal, Golden State Medical Supply, Long Term Care Group, ppoNEXT, SCI Solutions, U.S. Renal Care, Vantage Oncology, and Welltok.
Previously, Mohamad focused on growth equity investments at Summit Partners prior to which he worked with UBS Investment Bank. Mohamad received a bachelor's degree, with distinction, from the University of Pennsylvania and is a Board Member of The National Venture Capital Association (NVCA).
Melanie Nallicheri is a healthcare and life sciences executive with nearly three decades of experience. Melanie served as Chief Business Officer and Head, Biopharma for Foundation Medicine; Senior Vice President, Corporate Strategy and Business Development, McKesson Distribution Solutions and McKesson Data & Analytics; and Senior Vice President, Corporate Development at Geron Corporation. She holds an MBA with honors from Columbia Business School, and an M.S. in business and economics from WHU Otto Beisheim School of Corporate Management.
Rajeev Ronanki is the President of Digital Platforms at Anthem Inc. where he is reimagining the future of healthcare by harnessing the power of data and artificial intelligence (AI) to provide consumers predictive, proactive, and personalized insights into their health.
Since joining Anthem in 2018, Rajeev has led the organization’s digital-first transformation across Digital, AI, Exponential Technology, Service Experience, and Innovation portfolios. In his new role as President, Digital Platforms, Mr. Ronanki will continue to accelerate Anthem’s strategy to become a digital platform for health that utilizes a multi-channel approach to connect consumers, providers, employers, ecosystem partners, and more. To achieve this, Rajeev will create and execute the commercialization of Anthem’s digital capabilities to reinvent care delivery, operations, and interactions.
Over the last 20 years, Mr. Ronanki’s innovation-driven mindset, passion for social change, and in-depth industry knowledge has made him a regular speaker on topics related to navigating the future of healthcare, harnessing data driven insights, and delivering personalized experiences. In November 2021, Rajeev will also publish his first book, You And AI: A Citizen’s Guide to AI, Blockchain, and Puzzling Together the Future of Healthcare, which explores how exponential technologies can be integrated into a company’s DNA, creating AI-first, blockchain-first, data-first, technology-first digital enterprises for the twenty-first century and beyond.
Mr. Ronanki obtained a Bachelor’s Degree in Mechanical Engineering from Osmania University in India and a Master’s Degree in Computer Science from the University of Pennsylvania.
Michael Saad is a nationally recognized CIO named Becker’s Healthcare “Top 100 CIO’s to Know in 2021”.
Michael is the Senior Vice President and Chief Information Officer at the University of Tennessee Medical (UTMC) in Knoxville, TN. UTMC is the region’s only Level 1 trauma and academic medical center, including a 715-bed flagship hospital.
Michael joined UTMC in early 2016 as the CIO and has led healthcare transformation through innovative technology solutions. Michael led the organization to achieve CHIME’s Most Wired recognition, including a Performance Excellence designation and Level 9 status in 2021. Under Michael’s leadership, UTMC has received recognition for creating a robust cyber security program, implementing a patient wayfinding solution, and improving clinical care through various technology solutions.
Before joining UTMC, Michael was a senior consultant at TrustPoint Solutions based in Atlanta, GA. In this capacity, Michael worked with health systems across the country to develop strategic roadmaps and align IT with the business objectives. Additionally, Michael served as a trusted advisor to CIO’s and worked closely with executives to leverage technology solutions to address the needs of the business.
Prior to joining TrustPoint, Michael served as Vice President and Chief Technology Officer at Henry Ford Health System in Detroit. In addition to the responsibilities as CTO, Michael also served as the interim CIO for 18 months. Michael was responsible for the successful opening of a new hospital and led the successful implementation of several technology solutions. As CIO, Michael helped lead the organization to receive the Malcolm Baldrige Quality Award.
Michael is an active blogger and writer and has been featured in various national publications. He has been a guest on numerous podcasts and writes blog posts for Cioreflections.com. Michael is also a regular speaker at national technology conferences and serves as a member of the CNBC Technology Executive Council. Michael holds a bachelor of science degree in business management from Western Governors University.
Deena Shakir is a Partner at Lux Capital, where she invests in transformative technologies improving lives and livelihoods. She is particularly interested in intersectional and underdog entrepreneurs building breakthrough companies to accelerate advances and equity in human and population health.
Since joining Lux in late 2019, Deena has led a number of investments and currently sits on the boards of Maven Clinic, SteadyMD, Alife Health, H1, Adyn, AllStripes, and Shiru.
Prior to joining Lux, Deena was a Partner at GV (formerly Google Ventures), previously led product partnerships at Google for early stage products in healthcare, AI/ML and search at Google, and directed social impact investments at Google.org.
Before tech and venture, Deena had diverse partnership-centric experiences as an aspiring anthropologist, journalist, diplomat, aid worker and technologist. She was a Presidential Management Fellow at the U.S. Department of State under Secretary Clinton, where she helped launch President Obama’s first Global Entrepreneurship Summit in 2010. Her non-traditional path has cultivated Deena’s deep conviction in the potential of breakthrough ventures to positively transform the future and garnered her unparalleled network to help them achieve it.
A Forbes contributor, Deena is a frequent commentator and has been profiled in print and featured in broadcast in publications such as Fortune, Techcrunch, Marie Claire, Business Insider, Bloomberg, CNBC, and the Wall Street Journal. She was named a "top 30 under 40 in healthcare" by Business Insider, "top 9 women to watch in venture capital" by The Wall Street Journal, and "Top 50 in Digital Health" by Rock Health. She is a member of Fortune's Most Powerful Women, Kauffman Fellows, Aspen Finance Fellows and the Aspen Global Leadership Network, the Council on Foreign Relations, and All Raise.
Deena self-funded her education through a variety of merit scholarships and side hustles, including co-founding her first company while still in college. She earned a joint BA in Social Studies and Near Eastern Languages and Civilizations from Harvard (where she delivered the graduation address) and an MA from Georgetown’s School of Foreign Service. She is currently a Lecturer in the School of Engineering at the Stanford Design School.
Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.
Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.
Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."
She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.
Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Deirdre Bosa is a co-anchor of CNBC’s bi-coastal tech-focused program “TechCheck” (M-F, 11AM-12PM ET/8AM-9AM PT). Previously, Bosa served as a technology reporter based out of the network’s San Francisco Bureau, owning stories on the biggest names in tech from Amazon to Alphabet, key players in China’s tech scene like Alibaba and Huawei, and Silicon Valley’s largest disruptors from Airbnb to Uber to WeWork. Prior to that, she was a frequent presence on air and online as a CNBC contributor, reporting out of Vancouver, Canada.
Bosa joined CNBC in 2012 covering the markets and economies of London and Singapore. She has co-anchored morning programs including “Squawk Box Asia,” “Squawk Box Europe,” and “Worldwide Exchange.”
Prior to CNBC, Bosa was an anchor and reporter for CCTV News International based in Beijing, as well as a contributor to Fox Business News. Deirdre also worked for several multinational corporations including Barrick Gold in Toronto and Rio Tinto in Shanghai.
She is a graduate of McGill University in Montreal, Canada and University of Hong Kong’s Masters of Journalism program.
Contessa Brewer is a correspondent and substitute anchor for CNBC appearing throughout Business Day as well as the network’s 7pm ET newscast “The News with Shepard Smith.” She covers major news stories for CNBC including presidential elections, hurricanes, the coronavirus pandemic and trade wars. Her specialty coverage areas are casinos, the gaming industry and the insurance industry. Brewer joined the network in 2017 and is based at CNBC Global Headquarters.
A National Emmy-Award winning journalist, Brewer is known for her marathon on-air coverage of breaking news and big political stories. While an anchor for MSNBC, she hosted daily news programs and the long-running, primetime series “Caught on Camera.” As a correspondent, Brewer has contributed reports to CBS News, CBSN, WNBC, NBC News and MSNBC, where she covered a wide range of stories including presidential elections, debt ceilings, government shutdowns, natural disasters, terror attacks and celebrity news. She began her career in Reno, NV followed by Palm Springs, CA and Milwaukee, WI.
Brewer is a Remembrance Scholar and magna cum laude graduate of Syracuse University’s S.I. Newhouse School of Public Communication and Honors Program. She’s narrated several audiobooks and resides in New York with her husband, twin sons and a dappled dachshund.
Sharon Epperson, named one of “12 to Watch in TV News,” can be seen regularly on CNBC television and other media platforms.
As CNBC’s senior personal finance correspondent, Epperson covers the many facets of how people manage, grow and protect their money. Her expertise includes saving and investing for retirement, paying for college, managing mortgage, student loan, credit card and other debt, and building a financial legacy through estate planning.
Preparing your finances for the unexpected is another critical (and personal) aspect of her reporting. In September 2016, Epperson sustained a ruptured brain aneurysm and she nearly lost her life. She has become a staunch advocate for health and wellness issues, raising awareness about brain aneurysms and funding for research. In September 2018, she and her family established “The Sharon Epperson Chair of Research” through the Brain Aneurysm Foundation to provide grants for research on early detection and innovative treatments.
Epperson is a lead contributor to “Invest in You: Ready. Set. Grow.,” a multi-platform financial wellness and education initiative at CNBC in partnership with the micro-investing app Acorns, and developed its companion 8-week learning course and weekly newsletter, “Invest in You: Money 101.” She also contributes to NBC’s TODAY and NBC Nightly News as well as Today.com and NBCNews.com.
Her book, The Big Payoff: 8 Steps Couples Can Take to Make the Most of Their Money-and Live Richly Ever After, was a finalist for the Books for a Better Life Awards, honoring works that have “changed the lives of millions.” She also was a contributing writer for The Experts’ Guide to Doing Things Faster. Her personal finance expertise has been featured in numerous publications, including The Wall Street Journal, The Washington Post, The Boston Globe, USA Weekend, Self, Essence, Ebony and TIME, where she had covered business, culture, social issues and health as a correspondent prior to joining CNBC.
Epperson has numerous industry and civic awards, including the Special Achievement Award from the National Association of Personal Financial Advisors (NAPFA) and the Savvy Inspiration Award from the non-profit, financial empowerment group Savvy Ladies. She won an Alliance for Women in Media’s Gracie Award for Outstanding Online Host for her “Financial Advisor Playbook” video series on CNBC.com. She has received the Vanguard Award for her distinguished career in business and personal finance reporting from the National Urban League Guild, and the All-Star Award from the Association of Women in Communications. She also has won awards from the New York Festivals, the New York Association of Black Journalists and the National Association of Black Journalists.
Epperson is committed to improving financial literacy, particularly in underserved communities. She was invited to the White House during President Obama’s administration to speak about financial literacy and to moderate a public meeting of the President’s Advisory Council on Financial Capability at the U.S. Treasury Department. She also speaks frequently at conferences and events for local and national organizations, colleges and universities about many facets of personal finance.
An adjunct professor at Columbia University’s School of International and Public Affairs, Epperson has also taught courses at Columbia’s Graduate School of Journalism. She enjoys teaching the importance of budgeting and building long-term savings as part of her professional development courses for graduate students.
Epperson received her bachelor’s in sociology and government from Harvard University, a master of international affairs degree from Columbia University, and an honorary doctorate from Carlow University in Pittsburgh. A Pittsburgh native, she has also been inducted into the Hall of Fame at Taylor Allderdice High School, her alma mater.
She currently lives with her husband and two children in Westchester County, N.Y.
Phil LeBeau is a CNBC auto and airline industry reporter based at the network’s Chicago bureau. He is also editor of the Behind the Wheel section on CNBC.com.
LeBeau has reported one-hour documentaries for the network, including “Dreamliner: Inside the World’s Most Anticipated Airplane,” “Ford: Rebuilding an American Icon” and “Saving General Motors” and “Failure to Recall: Investigating GM,” which won a 2014 Society of American Business Editors and Writers (SABEW) Award.
Prior to joining CNBC, LeBeau served as a media relations specialist for Van Kampen Funds in Oak Brook Terrace, Ill., and was instrumental in implementing an initiative to communicate the company’s mutual fund and investment practices to the public and the press. While at Van Kampen, LeBeau held a Series 6 license.
Previously, he held general assignment reporting positions at KCNC-TV, the CBS affiliate in Denver, and KAKE-TV, the ABC affiliate in Wichita, Kan. LeBeau began his career as a field producer at WCCO-TV in Minneapolis, where he wrote, produced and researched consumer stories. He graduated from the University of Missouri-Columbia School of Journalism with a bachelor’s degree in journalism and broadcasting.
Melissa Lee is the host of CNBC’s “Fast Money” (Monday-Thursday, 5PM-6PM ET; Friday, 5PM-5:30PM ET), which originates from the Nasdaq’s MarketSite studio in New York’s Times Square. “Fast Money” gives you the information normally reserved for the Wall Street trading floor, enabling you to make decisions that can make you money. She is also the host of “Options Action,” (Friday, 5:30PM ET), a weekly half-hour program that explains the advantages of options trading.
In addition, Lee is a member of the ensemble cast of CNBC’s “Power Lunch” (M-F, 2PM-3PM ET).
Previously, Lee was co-anchor of CNBC’s “Squawk on the Street” and host of “Money in Motion Currency Trading.” She also covered investment banking, hedge funds and private equity for the network.
Lee has reported one-hour documentaries for the network, including “Rise of the Machines (2013),” “Code Wars: America’s Cyber Threat”(2011), ”Coca-Cola: The Real Story Behind the Real Thing” (2009) and ”Porn: Business of Pleasure” (2009). In 2008, Lee reported and anchored a one-hour documentary, “Made in China: People’s Republic of Profit,” from Beijing and Shanghai. She reported extensively for the network on China from the country’s growth to its challenges to the opportunities for U.S. businesses.
Lee received a 2010 Gracie Award for Outstanding Host-News and a Gerald Loeb Award nomination in 2009 for a CNBC Special Report: “Is Your Money Safe? The Fall of Lehman Brothers,” for which she co-anchored. Lee also has been nominated for two Emmy awards in Business News. In 2007, she was recognized for her report, “The $50M Con,” about a college student-turned scammer who ran a fake hedge fund and was ultimately caught by the FBI. And in 2003, she was nominated for her reporting on the proxy voting of mutual funds.
Prior to joining CNBC in 2004, Lee worked for Bloomberg Television and CNN Financial News.
Before her career in television, Lee was a consultant at Mercer Management Consulting. Her cases focused on the banking and credit card sectors.
Lee graduated with honors from Harvard College with a bachelor of arts in government. She also served as Assistant Managing Editor of the Harvard Crimson.
Tyler Mathisen co-anchors CNBC's "Power Lunch" (M-F, 1PM-3PM ET), one of the network's longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network's events team to grow the rapidly expanding business.
Previously, Mathisen was co-anchor of "Nightly Business Report," an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network's daily content and coverage. He was also co-anchor of CNBC's "Closing Bell."
Mathisen has reported one-hour documentaries for the network including "Best Buy: The Big Box Fights Back," "Supermarkets Inc: Inside a $500 Billion Money Machine" and "Death: It's a Living." Mathisen was also host of the CNBC series "How I Made My Millions."
Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine's mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.
In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on "Caring for Aging Parents," which aired on ABC's "Good Morning America." Mathisen served as money editor of "GMA" from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York's WCBS-TV.
A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.
Leslie Picker joined CNBC in February 2017 as a reporter covering hedge funds, private equity and asset management. She is based at CNBC Global Headquarters, and her reporting appears on television and CNBC’s digital platforms.
Picker has interviewed some of the most prominent investors on CNBC, including Citadel’s Ken Griffin, Greenlight Capital’s David Einhorn, Omega Advisors’ Leon Cooperman and Pershing Square’s Bill Ackman. Her investigation into Puerto Rico’s debt crisis won a Society for Advanced Business Editing and Writing (SABEW) award and was a finalist for a Gerald Loeb Award in 2018.
Previously, Picker was a reporter at The New York Times where she covered deals. Her beat encompassed mergers and acquisitions, initial public offerings, venture capital, private equity, restructuring and shareholder activism. Prior to The New York Times, Picker was a reporter at Bloomberg News where she reported on initial public offerings. There, she also contributed to Bloomberg Businessweek, Bloomberg Television and Bloomberg Radio. Prior to becoming a reporter, Picker was a segment producer for Bloomberg Television. She began her career as a booker at Fox Business Network.
Picker graduated magna cum laude from the University of Illinois, Urbana-Champaign, earning a bachelor’s degree in political science. She also earned a master’s in journalism from Columbia University, graduating with honors, and an MBA from New York University’s Stern School of Business, with a concentration in finance.
*Agenda subject to change
Tyler Mathisen, CNBC “Power Lunch” Co-Anchor & Vice President, Events Strategy
In his first sit-down interview, Johnson & Johnson’s new CEO Joaquin Duato shares his vision for the future of the world’s largest healthcare company and how he plans to continue to drive growth across the business.
Joaquin Duato, Johnson & Johnson Chief Executive Officer
Interviewer: Meg Tirrell, CNBC Health & Science Reporter
Last year was a banner year for digital health with nearly $60 billion invested into the sector globally. And VCs remain bullish on the long-term potential for health tech across multiple disruptive sectors including health IT, biopharma, medical devices and telehealth. Two leading health investors share their top tech picks that will transform health care in 2022 and beyond.
Deena Shakir, Lux Capital Partner
Mohamad Makhzoumi, NEA Managing General Partner, Healthcare
Moderator: Melissa Lee, CNBC “Fast Money” & “Options Action” Host
The global RNAi therapeutic market is expected to top $11. 5 billion by 2027, on the potential to cure a wide range of severe and debilitating diseases. Dr. Greenstreet walks us through the R&D breakthroughs and 2022 pipeline for this Nobel-winning “gene-silencing” technology.
Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals Chief Executive Officer
Interviewer: Meg Tirrell, CNBC Health & Science Reporter
The nature of the global airline business keeps Delta’s front-line teams (flight attendants, gate agents, customer service reps, maintenance crews, pilots) busy round the clock, 24/7. Taking care of the team’s physical health and mental wellness is a priority of the carrier’s leadership strategy. By investing in employee resilience and wellbeing, they in turn are better able to deliver a positive and safer travel experience for all its passengers.
Dr. Henry Ting, Delta Air Lines Chief Health Officer
Interviewer: Phil LeBeau, CNBC Auto & Airline Industry Reporter
Join the conversation on camera for these interactive, topic-based sessions led by industry leaders. Share your thoughts, ask questions, exchange ideas and network with event speakers and your peers.
The workplace has become more instrumental in employee health and wellness than ever before. Beyond standard benefits, employers have become a resource for mental health initiatives, testing, preventative care and much more, but as workers have shorter tenures at jobs today than in the past, could these initiatives have less staying power? Share your thoughts, ask questions, exchange ideas and network with members of our CNBC Workforce Executive Council and your peers.
Laura Birk, Barilla America Vice President, Human Resources
Kathleen Carroll, Grainger Senior Vice President and Chief Human Resources Officer
Jim Dunn, Atrium Health Chief People and Culture Officer
Moderator: Sharon Epperson, CNBC Personal Finance Correspondent
Big data and AI have unleashed a deluge of health tech start-ups and innovative ideas from mainstay companies. But for every great gadget, there’s often a flop. How do investors and prospective users know what’s a breakthrough and what isn’t; how concerned should users be about privacy and what’s the long-term outlook for the health care and technology industries working together? More mergers? New companies? Share your thoughts, ask questions, exchange ideas and network with members of our CNBC Technology Executive Council and your peers.
Rajeev Ronanki, Anthem President of Digital Platforms
Michael Saad, University of Tennessee Medical Center SVP and CIO
Moderator: Deirdre Bosa, “TechCheck” Co-Anchor
Since its launch a mere two years ago, EQRx’s bold – some say audacious – goal to develop and deliver new medicines at radically lower prices continues to shake up the drug market. A simple solution to a complex problem, according to backers like Google Ventures and Andreessen Horowitz, who are betting on a fast-moving pipeline, partnerships and lower costs to radically remake medicine for all.
Melanie Nallicheri, EQRx Chief Executive Officer
Interviewer: Tyler Mathisen, CNBC “Power Lunch” Co-Anchor & Vice President, Events Strategy
Two renowned nonprofit medical leaders and health equity advocates on the lessons learned from the pandemic, and ways to solve the health disparities that continue to divide our nation.
Dr. Nancy Brown, Yale School of Medicine Dean
Dr. Gary Désir, Yale School of Medicine Department of Internal Medicine Chair
Moderator: Contessa Brewer, CNBC Correspondent
After what has undoubtedly been a very rocky 12 months for biotech, is the sector ripe for a comeback? Biotech investor and Harvard-trained medical doctor, Dr. Christiana Bardon thinks advances in gene therapies, robust drug pipelines and an improving regulatory landscape will be key industry drivers for the road ahead.
Dr. Christiana Bardon, MPM Capital Co-Managing Partner
Interviewer: Leslie Picker, CNBC Finance and Investing Reporter
Major drugstore chains like Walgreens served as trusted health care hubs during the Covid-19 pandemic. It’s where Americans turned for testing, vaccinations, and hard to find goods close to home. The crisis came just as Walgreens looked to transform itself into a health care destination in the community, with digital and in-person primary care through VillageMD, and pharmacists playing a central role helping customers manage their health. In a rare interview, one year into her tenure, CEO Roz Brewer shares her vision for how Walgreens can bridge the care gap for patients and their caregivers in our fragmented health system.
Rosalind Brewer, Walgreens Boots Alliance Chief Executive Officer
Interviewer: Bertha Coombs, CNBC Reporter
Medallia is the pioneer and market leader in Experience Management. Medallia’s award-winning SaaS platform, the Medallia Experience Cloud, leads the market in the understanding and management of experience for customers, employees and citizens. Using Medallia customers can reduce churn, turn detractors into promoters and buyers and create in-the-moment cross-sell and up-sell opportunities, enabling clear returns on investment. www.medallia.com.
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Indigo. He is currently a Venture Partner at Flagship Pioneering. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Dr. Elaine Batchlor is the chief executive officer of Martin Luther King, Jr. Community Hospital, which opened in 2015. Dr. Batchlor was the driving force behind the effort to open the new, state-of-the-art, community-oriented, safety-net hospital providing compassionate, quality care and improving the health of the South Los Angeles community.
Throughout her career, Dr. Batchlor’s number one priority has been to improve access and quality of care for underserved communities utilizing innovative and collaborative approaches. Her work to increase access for underserved populations has been recognized as an example of leading best practices and adopted throughout California.
Before assuming the helm of Martin Luther King, Jr. Community Hospital, Dr. Batchlor served on the executive leadership team of L.A. Care Health Plan, the nation’s largest public health plan. As chief medical officer, she was instrumental in developing a care delivery model that expanded access and resources to more than a million individuals throughout the county.
She spearheaded provider use of information technology and telemedicine to improve access and quality of care for Los Angeles County’s Medi-Cal (Medicaid) population. Under her leadership, L.A. Care established the Health Information Technology Extension Center, becoming the second health plan in the nation to operate a Regional Extension Center to help safety-net providers adopt and use electronic health records. She implemented eConsult, an innovative electronic physician-to-specialist consultation and referral system, for Los Angeles County community health centers and the Los Angeles County Department of Health Services.
Prior to L.A. Care, Dr. Batchlor served in leadership positions at the California HealthCare Foundation, the Los Angeles County Department of Health Services, Prudential Health Care, and Ross Loos Medical Group. Early in her career she served as a clinical instructor at the UCLA School of Medicine.
Dr. Batchlor is an active community volunteer, serving on multiple community and healthcare boards. She has a particular interest in mentoring youth. She regularly meets with students, from high school through professional school, who are interested in careers in healthcare. Formerly, she served on advisory boards for the UCLA Fielding School of Public Health, the UCLA National Clinical Scholars, and the UCLA Academic Advancement Program Advisory Council. Recently, she was elected to the National Academy of Medicine, an academy committed to the health for all by advancing science, accelerating health equity, and providing independent, authoritative, and trusted advice nationally and globally. A Harvard alumna, Dr. Batchlor serves as an interviewer for Harvard College applicants and as a liaison to a local high school.
She served as the past chair and is currently on the board of the Integrated Healthcare Association. She is a member of the Board of Trustees of the California Association of Hospitals and Health Systems, the boards of directors of the Healthcare Quality Institute and California Health and Wellness, and the editorial board of Health Affairs, the leading peer-reviewed journal of health policy thought and research.
Dr. Batchlor received a Bachelor of Arts degree from Harvard University, a Master of Public Health degree from the University of California, Los Angeles, and a Doctorate in Medicine degree from Case Western Reserve University. She completed internship, residency, and fellowship training in internal medicine and rheumatology at Harbor-UCLA Medical Center and is board-certified in both specialties.
She is married to a lawyer who has spent his career representing indigent clients, currently working for the Los Angeles County Public Defender’s Office. The couple has twin boys.
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.
Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.
Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.
The developer of a comprehensive, patient-centric electronic medical record (EMR) system and founder of Epic Systems Corporation, Judith Faulkner is recognized for her scientific and technological leadership. Her vision for health care technology is both comprehensive and simple: provide the relevant medical information when it's needed, do what's best for the patient, and help clinicians collaborate. Her innovative health information technology infrastructure allows for the implementation of workflow steps, clinical guidelines, and best-practice alerts tailored to each clinician's role in patient care while on the patient end providing information regarding prescriptions, appointments, communication with the care team, and prevention/treatment reminders.
Epic EMR systems do away with traditional paper files and provide a single, shared patient record which can be accessed by clinical staff across all manner of health care services and, with proper consent, across different health care organizations. Given the complexity and magnitude of medical data that may be included, the technological challenge has been to develop this comprehensive infrastructure for diverse health care settings while scaling to millions of records and thousands of concurrent users who all require rapid response times.
Independent studies have documented the positive impact of Epic technologies on the quality of clinical care and the software has led to improvements in medical research. To date, 240 health care organizations use Epic technologies to provide medical care to approximately 118 million people. This includes fourteen Wisconsin organizations that increasingly serve as the early adopters of the latest advances in Epic's health technologies.
Faulkner has led Epic strategically and operationally to create state-of-the-art technologies that improve the quality, safety, and efficiency of health care across Wisconsin, the United States, and, increasingly, the world.
Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She joined Merck in 2010 as president of Merck vaccines
Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through 40+ emergency responses to public health crises. She serves on the Boards of Biotechnology Innovation Organization (BIO), Cerner Corporation and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries.
Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year and received the Lifetime Achievement Award from eyeforpharma.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine. Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians. She is board certified in Internal Medicine and Infectious Diseases.
Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.
Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.
Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.
A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.
Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.
Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.
Vasant (Vas) Narasimhan, M.D., has been Chief Executive Officer (CEO) of Novartis since February 1, 2018.
Dr. Narasimhan previously was Global Head of Drug Development and Chief Medical Officer for Novartis. He has also served as Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.
Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.
Arif Nathoo, M.D., is co-founder & chief executive officer at Komodo Health where he oversees data sciences, engineering, and product development initiatives for the company. He has spent the past 15 years in healthcare and life sciences leadership roles. Before Komodo Health, Arif was a leader in McKinsey’s Healthcare practice where he was responsible for helping enterprise healthcare address issues in corporate strategy, finance, sales and marketing, and organization building. He co-led McKinsey’s Medical Affairs Practice, which created analytic products and services to improve non-promotional engagement between industry and providers.
He has conducted research in novel instructional technologies and medical devices, with multiple publications in peer-reviewed journals. Arif graduated magna cum laude with Highest Honors from Harvard University with an A.M. in molecular and cellular biology, an M.D. from Harvard Medical School, and M.P.A. in health policy from Harvard Kennedy School.
Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.
Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.
In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).
Leonard S. Schleifer, MD, PhD, founded Regeneron Pharmaceuticals in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a director, its president and chief executive officer since its inception and acted as chairman of the board from 1990 through 1994. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.
Rochelle P. Walensky, MD, MPH, is the 19th Director of the Centers for Disease Control and Prevention and the ninth Administrator of the Agency for Toxic Substances and Disease Registry. She is an influential scholar whose pioneering research has helped advance the national and global response to HIV/AIDS. Dr. Walensky is also a well-respected expert on the value of testing and treatment of deadly viruses.
Dr. Walensky served as Chief of the Division of Infectious Diseases at Massachusetts General Hospital from 2017-2020 and Professor of Medicine at Harvard Medical School from 2012-2020. She served on the frontline of the COVID-19 pandemic and conducted research on vaccine delivery and strategies to reach underserved communities.
Dr. Walensky is recognized internationally for her work to improve HIV screening and care in South Africa and nationally recognized for motivating health policy and informing clinical trial design and evaluation in a variety of settings.
She is a past Chair of the Office of AIDS Research Advisory Council at the National Institutes of Health, Chair-elect of the HIV Medical Association, and previously served as an advisor to both the World Health Organization and the Joint United Nations Programme on HIV/AIDS.
Originally from Maryland, Dr. Walensky received her Bachelor of Arts from Washington University in St. Louis, her Doctor of Medicine from the Johns Hopkins School of Medicine, and her Masters in Public Health from the Harvard School of Public Health.